Literature DB >> 18723908

Efficacy of two dose regimes of intravenous immunoglobulin in Rh hemolytic disease of newborn--a randomized controlled trial.

G Girish1, D Chawla, R Agarwal, V K Paul, A K Deorari.   

Abstract

OBJECTIVE: To compare the effect of two dose regimes of IVIg (0.5 g/kg vs. 1g/kg given soon after birth) on duration of phototherapy in Rh-isoimmunized neonates 32 week and above gestation.
DESIGN: Randomized controlled trial.
SETTING: Tertiary care hospital.
SUBJECTS: Rh positive blood group neonates of gestation 32 weeks and above born to Rh negative mothers having positive Direct Coombs test and without any major malformation. INTERVENTION: Intravenous immunoglobulin (IVIg) infusion over 2 h either 0.5 g/kg (low dose group, n=19) or 1.0 g/kg (high dose group, n=19). PRIMARY OUTCOME VARIABLE: Duration of phototherapy.
RESULTS: The mean duration of phototherapy was 77.3+/-57.2 h in low dose group versus 55.4+/-49 h in high dose group (mean difference=21.9; 95% CI-13.1 to 56.9). There was no difference in need for exchange transfusion (21% in both the groups) and requirement of packed red blood cells transfusion (12 transfusions in both groups). The duration of hospital stay was similar [8.4+/-6.9 and 13.6+/-14.8 days, respectively (mean difference=-5.1; 95% CI-12.8 to 2.5)]. No adverse effects of IVIg administration were noted.
CONCLUSION: Two regimens of IVIg (0.5 g/Kg or 1 g/Kg) had comparable effect on duration of phototherapy, duration of hospital stay and exchange transfusion requirement, in Rh isoimmunized neonates of gestation 32 weeks and above.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18723908

Source DB:  PubMed          Journal:  Indian Pediatr        ISSN: 0019-6061            Impact factor:   1.411


  5 in total

1.  Early intravenous immunoglobin (two-dose regimen) in the management of severe Rh hemolytic disease of newborn--a prospective randomized controlled trial.

Authors:  Mohsen Saleh Elalfy; Nancy Samir Elbarbary; Heba Wegdan Abaza
Journal:  Eur J Pediatr       Date:  2010-10-06       Impact factor: 3.183

2.  Intravenous Immunoglobulin G Treatment in ABO Hemolytic Disease of the Newborn, is it Myth or Real?

Authors:  Serdar Beken; Ibrahim Hirfanoglu; Canan Turkyilmaz; Nilgun Altuntas; Sezin Unal; Ozden Turan; Esra Onal; Ebru Ergenekon; Esin Koc; Yildiz Atalay
Journal:  Indian J Hematol Blood Transfus       Date:  2012-08-28       Impact factor: 0.900

Review 3.  Hyperbilirubinemia in Neonates: Types, Causes, Clinical Examinations, Preventive Measures and Treatments: A Narrative Review Article.

Authors:  Sana Ullah; Khaista Rahman; Mehdi Hedayati
Journal:  Iran J Public Health       Date:  2016-05       Impact factor: 1.429

4.  Hemolytic anemia caused by non-D minor blood incompatibilities in a newborn.

Authors:  Ali Ulas Tugcu; Deniz Anuk Ince; Ozden Turan; Burcu Belen; Lale Olcay; Ayse Ecevit
Journal:  Pan Afr Med J       Date:  2019-07-29

Review 5.  Immunoglobulin for alloimmune hemolytic disease in neonates.

Authors:  Carolien Zwiers; Mirjam Ea Scheffer-Rath; Enrico Lopriore; Masja de Haas; Helen G Liley
Journal:  Cochrane Database Syst Rev       Date:  2018-03-18
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.